Frontiers in Immunology (Jan 2024)
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream
- Luana Calabrò,
- Luana Calabrò,
- Giuseppe Bronte,
- Giuseppe Bronte,
- Federica Grosso,
- Luigi Cerbone,
- Angelo Delmonte,
- Fabio Nicolini,
- Massimiliano Mazza,
- Anna Maria Di Giacomo,
- Anna Maria Di Giacomo,
- Alessia Covre,
- Alessia Covre,
- Alessia Covre,
- Maria Fortunata Lofiego,
- Maria Fortunata Lofiego,
- Maria Fortunata Lofiego,
- Lucio Crinò,
- Michele Maio,
- Michele Maio,
- Michele Maio,
- Michele Maio
Affiliations
- Luana Calabrò
- Department of Translational Medicine, University of Ferrara, Ferrara, Italy
- Luana Calabrò
- Department of Oncology, University Hospital of Ferrara, Ferrara, Italy
- Giuseppe Bronte
- Department of Clinical and Molecular Sciences (DISCLIMO), Università Politecnica Delle Marche, Ancona, Italy
- Giuseppe Bronte
- Clinic of Laboratory and Precision Medicine, National Institute of Health and Sciences On Ageing (IRCCS INRCA), Ancona, Italy
- Federica Grosso
- Mesothelioma, Melanoma and Sarcoma Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
- Luigi Cerbone
- Mesothelioma, Melanoma and Sarcoma Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
- Angelo Delmonte
- Department of Medical Oncology, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
- Fabio Nicolini
- IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
- Massimiliano Mazza
- IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
- Anna Maria Di Giacomo
- Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Siena, Italy
- Anna Maria Di Giacomo
- Center for Immuno-Oncology, University of Siena, Siena, Italy
- Alessia Covre
- Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Siena, Italy
- Alessia Covre
- Center for Immuno-Oncology, University of Siena, Siena, Italy
- Alessia Covre
- 0EPigenetic Immune-Oncology Consortium Airc (EPICA), Siena, Italy
- Maria Fortunata Lofiego
- Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Siena, Italy
- Maria Fortunata Lofiego
- Center for Immuno-Oncology, University of Siena, Siena, Italy
- Maria Fortunata Lofiego
- 0EPigenetic Immune-Oncology Consortium Airc (EPICA), Siena, Italy
- Lucio Crinò
- Department of Medical Oncology, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
- Michele Maio
- Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Siena, Italy
- Michele Maio
- Center for Immuno-Oncology, University of Siena, Siena, Italy
- Michele Maio
- 0EPigenetic Immune-Oncology Consortium Airc (EPICA), Siena, Italy
- Michele Maio
- 1Fondazione Network Italiano per la Bioterapia dei Tumori (NIBIT) Onlus, Siena, Italy
- DOI
- https://doi.org/10.3389/fimmu.2023.1333661
- Journal volume & issue
-
Vol. 14
Abstract
Pleural mesothelioma (PM) is an aggressive and rare disease, characterized by a very poor prognosis. For almost two decades, the world standard treatment regimen for unresectable PM has consisted of a platinum-based drug plus pemetrexed, leading to an overall survival of approximately 12 months. The dramatic therapeutic scenario of PM has recently changed with the entry into the clinic of immune checkpoint inhibition, which has proven to be an effective approach to improve the survival of PM patients. The aim of the present review is to provide a comprehensive overview of the most promising immunotherapeutic-based strategies currently under investigation for advanced PM.
Keywords
- pleural mesothelioma
- immunotherapy
- immune checkpoint inhibitors
- adoptive cell therapy
- epigenetic drugs
